Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 25;11(7):1109.
doi: 10.3390/cells11071109.

Newborn Screening: Review of its Impact for Cystinosis

Katharina Hohenfellner  1 , Ewa Elenberg  2 , Gema Ariceta  3 , Galina Nesterova  4 , Neveen A Soliman  5 , Rezan Topaloglu  6
Affiliations
Review

Newborn Screening: Review of its Impact for Cystinosis

Katharina Hohenfellner et al. Cells. .

Abstract

Newborn screening (NBS) programmes are considered to be one of the most successful secondary prevention measures in childhood to prevent or reduce morbidity and/or mortality via early disease identification and subsequent initiation of therapy. However, while many rare diseases can now be detected at an early stage using appropriate diagnostics, the introduction of a new target disease requires a detailed analysis of the entire screening process, including a robust scientific background, analytics, information technology, and logistics. In addition, ethics, financing, and the required medical measures need to be considered to allow the benefits of screening to be evaluated at a higher level than its potential harm. Infantile nephropathic cystinosis (INC) is a very rare lysosomal metabolic disorder. With the introduction of cysteamine therapy in the early 1980s and the possibility of renal replacement therapy in infancy, patients with cystinosis can now reach adulthood. Early diagnosis of cystinosis remains important as this enables initiation of cysteamine at the earliest opportunity to support renal and patient survival. Using molecular technologies, the feasibility of screening for cystinosis has been demonstrated in a pilot project. This review aims to provide insight into NBS and discuss its importance for nephropathic cystinosis using molecular technologies.

Keywords: CTNS-pathogenic variants; clinical course; infantile nephropathic cystinosis; newborn screening; newborn screening for cystinosis.

PubMed Disclaimer

Conflict of interest statement

K.H., E.E., N.A.S. and G.N. have no competing interest. G.A. has received honoraria for lectures, presentations, or educational events from Alexion Pharmaceuticals, Recordati Rare Disease, Advicenne, Chiesi, Kyowa Kirim, support for attending meetings from Recordati Rare Disease, Kyowa Kirim, and Advicenne and for participating on Advisory Boards for Alexion Pharmaceuticals, Advicenne, Dicerna, and Alnylam. R.T. has received honorarium for lectures from Recordati and Alnylam.

Figures

Figure 1
Figure 1
Test results and quality parameters in neonatal screening. Sensitivity: Ability of the test to accurately identify those individuals with a specific condition/disease. Specificity: Ability of the test to accurately identify those individuals without the condition/disease. Positive predictive value (PPV): Probability that the person tested has the disease when the test is positive. Negative predictive value: Probability that the person does not have the disease, when the test is negative.
See this image and copyright information in PMC

References

    1. Therrell B.L., Padilla C.D., Loeber J.G., Kneisser I., Saadallah A., Borrajo G.J., Adams J. Current status of newborn screening worldwide: 2015. Semin. Perinatol. 2015;39:171–187. doi: 10.1053/j.semperi.2015.03.002. - DOI - PubMed
    1. Cornel M., Rigter T., Weinreich S., Burgard P., Hoffmann G.F., Lindner M., Loeber J.G., Rupp K., Taruscio D., Vittozzi L. Newborn Screening in Europe Expert Opinion. [(accessed on 13 February 2022)]. Available online: https://isns-neoscreening.org.
    1. World Health Organization Screening Programmes: A Short Guide. [(accessed on 13 February 2022)]. Available online: https://apps.who.int/iris/bitstream/handle/10665/330829/9789289054782-en....
    1. Therrell B.L., Lloyd-Puryear M.A., Ohene-Frempong K., Ware R.E., Padilla C.D., Ambrose E.E., Barkat A., Ghazal H., Kiyaga C., Mvalo T., et al. Empowering newborn screening programs in African countries through establishment of an international collaborative effort. J. Community Genet. 2020;11:253–268. doi: 10.1007/s12687-020-00463-7. - DOI - PMC - PubMed
    1. Loeber J., Platis D., Zetterström R., Almashanu S., Boemer F., Bonham J., Borde P., Brincat I., Cheillan D., Dekkers E., et al. Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. Int. J. Neonatal Screen. 2021;7:15. doi: 10.3390/ijns7010015. - DOI - PMC - PubMed